Featured
-
-
Review Article |
Targeting signalling pathways and the immune microenvironment of cancer stem cells — a clinical update
Cancer stem cells (CSCs) are implicated in cancer development, progression and resistance to treatment; therefore, the signalling pathways that mediate the CSC phenotype are attractive therapeutic targets. In this Review, the authors provide an update on the progress in targeting the Notch, WNT, Hedgehog and Hippo signalling pathways. Additionally, they discuss the interactions of CSCs with the immune system, the roles of CSC-related signalling pathways in immune cells and novel approaches to CSC-directed immunotherapy.
- Joseph A. Clara
- , Cecilia Monge
- & Naoko Takebe
-
Research Highlight |
BCC identity switch breaks restraints of Hedgehog pathway inhibition
- David Killock
-
Comment |
Disseminated breast tumour cells: biological and clinical meaning
We posit that disseminating tumour cells detected in the bone marrow or in the circulation are either cancer stem cells with full metastatic potential, tumour-bulk cells, or dormant cancer cells. This model has both therapeutic and diagnostic implications, raising concern over inadequate treatment as well as the possibility of overtreatment resulting from overdiagnosis.
- Klaus Pantel
- & Daniel F. Hayes
-
Review Article |
EMT, CSCs, and drug resistance: the mechanistic link and clinical implications
According to the cancer stem cell (CSC) paradigm, a minor subpopulation of cancer cells with stem-cell properties predominantly underlies tumour progression, therapy resistance, and disease recurrence. Notably, epithelial-to-mesenchymal transition (EMT) is implicated in these processes, and CSCs typically show markers of EMT-programme activation. Herein, the authors outline our current understanding of the links between the EMT programme, the CSC phenotype, metastasis, and drug resistance, and discuss the potential for therapeutic targeting of these facets of tumour biology.
- Tsukasa Shibue
- & Robert A. Weinberg
-
-
Research Highlight |
Periostin—a new potential target for the treatment of glioblastoma
- Alessia Errico
-
-
Research Highlight |
Mutations in breast cancer stem cells correlate with metastases
- Vanessa Marchesi
-
Review Article |
Emerging targeted agents in metastatic breast cancer
There have been great advances in the treatment of patients with breast cancer, with novel targeted agents having a great impact on treatment at all stages of the disease trajectory. In this Review, the treatment options for patients with metastatic disease are discussed—focussing on agents that target breast cancer cells, breast cancer stem cells and the breast microenvironment.
- Dimitrios Zardavas
- , José Baselga
- & Martine Piccart
-
-
In Brief |
Circulating tumor cells predict for bad news
-
Review Article |
Targeting cancer stem cells by inhibiting Wnt, Notch, and Hedgehog pathways
Selectively targeting cancer stem cells with novel therapeutics is gaining importance because disease recurrence after treatment-induced remissions is a major cause of morbidity and mortality. This Review discusses the pathways that are active during development, specifically the Wnt, Notch, and Hedgehog pathways, and the clinical development of therapeutic agents that target these pathways.
- Naoko Takebe
- , Pamela J. Harris
- & S. Percy Ivy
-
Cancer-related accelerated ageing and biobehavioural modifiers: a framework for research and clinical care